

**Correction**

Liliana Michelle Gomez Mendez, Matthew D. Cascino, Jay Garg, Tamiko R. Katsumoto, Paul Brakeman, Maria Dall’Era, Richard John Looney, Brad Rovin, Leonard Dragone, Paul Brunetta: Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. *Clin J Am Soc Nephrol* 13: 1502–1509; published ahead of print August 8, 2018, doi: 10.2215/CJN.01070118.

Due to author error, the Clinicaltrials.gov identifier was incorrectly listed in the article as indicated below. The correct trial number identifier is NCT02550652.

“The NOBILITY study is an ongoing phase II trial in subjects with proliferative lupus nephritis randomized to either obinutuzumab or placebo plus background therapy of mycophenolate and steroids (clinicaltrials.gov identifier NCT01905943) that aims to test the hypothesis that greater B-cell depletion can lead to increased rates of response in subjects with lupus nephritis.”

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).